Isobutyramide, N-heptyl-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Isobutyramide, N-heptyl-
• 英文别名: N-heptyl-2-methylpropanamide
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: DDISCKVQXLSOGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN<br/>[FR] AGENTS DE DÉGRADATION DE LA PROTÉINE NS3/4A DU VIRUS DE L'HÉPATITE C
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2020069125A1

  公开（公告）日：2020-04-02

  Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3/4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.

  本文披露了针对丙型肝炎病毒（HCV）NS3/4A进行降解的双功能化合物（降解剂）。还披露了含有这些降解剂的药物组合物以及使用这些化合物治疗HCV感染和HCV相关疾病或紊乱的方法。
• MACROCYCLIC COMPOUNDS FOR MODULATING IL-17
  申请人：ENSEMBLE THERAPEUTICS CORPORATION

  公开号：US20150005319A1

  公开（公告）日：2015-01-01

  The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.

  本发明涉及公式I的大环化合物及其治疗用途。更具体地，本发明涉及调节IL-17活性或用于治疗医疗情况（例如炎症性疾病和其他IL-17相关疾病）的大环化合物。
• Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10369140B2

  公开（公告）日：2019-08-06

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

  本发明提供了式 (I) 的化合物： 或其立体异构体，或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是单酰基甘油酰基转移酶 2 型（MGAT2）抑制剂，可用作药物。
• COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140186923A1

  公开（公告）日：2014-07-03

  Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.
• ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170216263A1

  公开（公告）日：2017-08-03

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.